


# PRODUCT INFORMATION



## NPS 2390

Item No. 11989

**CAS Registry No.:** 226878-01-9  
**Formal Name:** N-tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-yl-2-quinoxalinecarboxamide  
**MF:** C<sub>19</sub>H<sub>21</sub>N<sub>3</sub>O  
**FW:** 307.4  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 202, 243, 327 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

NPS 2390 is supplied as a crystalline solid. A stock solution may be made by dissolving the NPS 2390 in the solvent of choice, which should be purged with an inert gas. NPS 2390 is soluble in organic solvents such as ethanol and dimethyl formamide. The solubility of NPS 2390 in these solvents is approximately 0.25 mg/ml.

### Description

Metabotropic glutamate receptors (mGluRs), mediate excitatory synaptic transmission in the central nervous system. Potent and selective antagonists of the type I mGluRs (mGluR1 and mGluR5) are of interest as novel therapeutics for the treatment of various CNS disorders, such as pain, epilepsy, and stroke.<sup>1,2</sup> NPS 2390 is a first generation quinoline derivative that acts as a noncompetitive antagonist of mGluR1 and mGluR5 with IC<sub>50</sub> values equal to 5.2 and 82 nM, respectively.<sup>3</sup> At concentrations up to 30 μM, NPS 2390 does not affect mGluR2 or mGluR8 or a standard collection of 37 additional receptors, ion channels, and enzymes.<sup>3</sup> At a dose of 10 mg/kg, NPS 2390 displaced the specifically bound mGluR1R-selective antagonist, [<sup>3</sup>H]R214127, in rat cerebellum.<sup>4</sup>

### References

1. Ferraguti, F., Crepaldi, L., and Nicoletti, F. Metabotropic glutamate 1 receptor: Current concepts and perspectives. *Pharmacol. Rev.* **60(4)**, 536-581 (2008).
2. Mabire, D., Coupa, S., Adelinet, C., *et al.* Synthesis, structure-activity relationship, and receptor pharmacology of a new series of quinoline derivatives acting as selective, noncompetitive mGlu1 antagonists. *J. Med. Chem.* **48(6)**, 2134-2153 (2005).
3. VanWagenen, B.C., Smith, D.L., Artman, L.D., *et al.* Structure-activity relationship studies of NPS 2390: A potent and selective group I metabotropic glutamate receptor antagonist. *Soc. Neurosci.* 1-2 (2000).
4. Lavreysen, H., Janssen, C., Bischoff, F., *et al.* [<sup>3</sup>H]R214127: A novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. *Mol. Pharmacol.* **63(5)**, 1082-1093 (2003).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/28/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM